PDCD1 and neoplasm: Nowadays, the PD-1/PD-L1 checkpoint blockade immunotherapy showed satisfactory efficacy as well as low toxicity in advanced HNSC patients; however, due to the important role of PD-1 in tumor antigen tolerance, the curative effects of PD-1 therapy in some patients was poor (39, 40).